Effective as of July 28, 2023 (Transition Date), Dr. Mark Murphy and ProSomnus, Inc. (Company) agreed that Dr. Murphy will resume his Lead Faculty role and will relinquish his role as the Company?s Chief Growth Officer. In the Lead Faculty role, Dr. Murphy will focus his attention on the clinical applications of the Company?s products and expanding relationships within the clinical and scientific communities and will relinquish his policy setting and administrative responsibilities. Dr. Murphy?s transition is not related to any disagreement between Dr. Murphy and the Company.

As of the Transition Date, Dr. Murphy ceased to be an ?executive officer? for purposes of Item 401(b) of Regulation S-K and an ?officer? of the Company for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.